Trial Profile
A PHASE 1, NON-RANDOMIZED, OPEN-LABEL, SINGLE-DOSE STUDY TO EVALUATE THE PHARMACOKINETICS, SAFETY AND TOLERABILITY OF PF-04965842 IN SUBJECTS WITH RENAL IMPAIRMENT AND IN HEALTHY SUBJECTS WITH NORMAL RENAL FUNCTION
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 21 Oct 2021
Price :
$35
*
At a glance
- Drugs Abrocitinib (Primary)
- Indications Atopic dermatitis
- Focus Pharmacokinetics
- Sponsors Pfizer
- 12 Oct 2021 Results investigating effects of renal impairment on the pharmacokinetics of Abrocitinib and its metabolites, published in the Journal of Clinical Pharmacology
- 21 Nov 2019 Status changed from recruiting to completed.
- 11 Nov 2019 Planned End Date changed from 21 Jan 2020 to 5 Nov 2019.